Literature DB >> 24388667

Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.

Jeffrey J Swigris1, David L Streiner2, Kevin K Brown3, Amanda Belkin3, Kathy E Green4, Frederick S Wamboldt5.   

Abstract

BACKGROUND: Dyspnea is a hallmark symptom of idiopathic pulmonary fibrosis (IPF), and dyspnea induced physical activity limitation is a prominent driver of quality of life impairment among IPF patients.
METHODS: We examined response data for the 21 physical activity items (the first 21 of 24) from the University of California San Diego Shortness of Breath Questionnaire (UCSD) collected at baseline in a recently conducted IPF trial. We used Rasch analysis and hypothesis testing with conventional statistical methodology to achieve three objectives: 1) to examine the items to identify the one characteristic that distinguishes one from another; 2) to asses these items for their ability to measure dyspnea severity in IPF; 3) to use the items to develop a dyspnea ruler.
RESULTS: The sample comprised 178 subjects. The 21 items fit the Rasch model. There was very strong correlation between Rasch item severity and their metabolic equivalents (METS) values (r = -0.86, p < 0.0001). With the sample stratified on scores from the 21 items, there were significant between group differences in FVC%, DLCO% and distance walked during the six-minute walk test. The dyspnea ruler can be used to put dyspnea levels in a more easily understood clinical context.
CONCLUSIONS: The first 21 items from the UCSD compose a unidimensional dyspnea-with-activity scale and are both sensibly ordered and distinguished from each other by their METS values. These 21 items can be used confidently to formulate clinically-relevant inferences about IPF patients and should be considered for use as a meaningful endpoint in IPF research.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dyspnea; Functional capacity; Idiopathic pulmonary fibrosis; Quality of life

Mesh:

Substances:

Year:  2013        PMID: 24388667      PMCID: PMC3951298          DOI: 10.1016/j.rmed.2013.12.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Characterizing and quantifying the symptomatic features of COPD exacerbations.

Authors:  Paul W Jones; Wen-Hung Chen; Teresa K Wilcox; Sanjay Sethi; Nancy Kline Leidy
Journal:  Chest       Date:  2010-11-11       Impact factor: 9.410

2.  2011 Compendium of Physical Activities: a second update of codes and MET values.

Authors:  Barbara E Ainsworth; William L Haskell; Stephen D Herrmann; Nathanael Meckes; David R Bassett; Catrine Tudor-Locke; Jennifer L Greer; Jesse Vezina; Melicia C Whitt-Glover; Arthur S Leon
Journal:  Med Sci Sports Exerc       Date:  2011-08       Impact factor: 5.411

3.  Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011.

Authors:  G Raghu
Journal:  Eur Respir J       Date:  2011-04       Impact factor: 16.671

4.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Meilan Han; Rekha Vij; Imre Noth; Eric L Eisenstein; Kevin J Anstrom; Kevin K Brown; Diane Fairclough
Journal:  Respir Med       Date:  2012-07-15       Impact factor: 3.415

5.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake
Journal:  N Engl J Med       Date:  2010-05-18       Impact factor: 91.245

Review 6.  Health-related quality of life among patients with idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Michael K Gould; Sandra R Wilson
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

7.  Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire.

Authors:  Janelle Yorke; Paul W Jones; Jeffrey J Swigris
Journal:  Thorax       Date:  2010-10       Impact factor: 9.139

8.  Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego.

Authors:  E G Eakin; P M Resnikoff; L M Prewitt; A L Ries; R M Kaplan
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

9.  Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12.

Authors:  J Yorke; S H Moosavi; C Shuldham; P W Jones
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

10.  Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire.

Authors:  Makiko Meguro; Elizabeth A Barley; Sally Spencer; Paul W Jones
Journal:  Chest       Date:  2007-07-23       Impact factor: 9.410

  10 in total
  7 in total

1.  Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis.

Authors:  Amy L Olson; Bridget Graney; Susan Baird; Tara Churney; Kaitlin Fier; Marjorie Korn; Mark McCormick; David Sprunger; Thomas Vierzba; Frederick S Wamboldt; Jeffrey J Swigris
Journal:  BMC Pulm Med       Date:  2017-11-22       Impact factor: 3.317

2.  Pulmonary oxygen uptake and muscle deoxygenation kinetics during heavy intensity cycling exercise in patients with emphysema and idiopathic pulmonary fibrosis.

Authors:  Melitta A McNarry; Nicholas K Harrison; Tom Withers; Narendra Chinnappa; Michael J Lewis
Journal:  BMC Pulm Med       Date:  2017-01-31       Impact factor: 3.317

3.  The 1-minute sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease.

Authors:  Justine Briand; Hélène Behal; Cécile Chenivesse; Lidwine Wémeau-Stervinou; Benoit Wallaert
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

4.  Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial.

Authors:  Bridget A Graney; David H Au; Anna E Barón; Andrew Cheng; Sara A Combs; Thomas J Glorioso; Grady Paden; Elizabeth C Parsons; Borsika A Rabin; Debra P Ritzwoller; Jessica-Jean Stonecipher; Carolyn Turvey; Carolyn H Welsh; David B Bekelman
Journal:  Trials       Date:  2019-06-13       Impact factor: 2.279

5.  An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis.

Authors:  Mohleen Kang; Srihari Veeraraghavan; Greg S Martin; Jordan A Kempker
Journal:  ERJ Open Res       Date:  2021-10-18

6.  Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.

Authors:  Xin Geng; Kobina Dufu; Athiwat Hutchaleelaha; Qing Xu; Zhe Li; Chien-Ming Li; Mira P Patel; Nicholas Vlahakis; Josh Lehrer-Graiwer; Donna Oksenberg
Journal:  Physiol Rep       Date:  2016-09

Review 7.  A systematic review of literature to evaluate the burden of physical and psychological symptoms and palliative care in patients diagnosed with idiopathic pulmonary fibrosis.

Authors:  M F van Jaarsveld; L Gwyther
Journal:  Afr J Thorac Crit Care Med       Date:  2019-04-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.